Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of cancer"
DOI: 10.1016/j.ejca.2020.09.007
Abstract: BACKGROUND Pre-therapeutic UGT1A1 genotyping is not yet routinely performed in most hospitals in patients starting irinotecan chemotherapy. The aim of this position paper was to evaluate the available evidence and to assess the potential value… read more here.
Keywords: irinotecan induced; induced severe; severe toxicity; pre therapeutic ... See more keywords
Prediction of severe toxicity in adult patients under treatment with 5-fluorouracil: a prospective cohort study
Sign Up to like & getrecommendations! Published in 2017 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000000546
Abstract: 5-Fluorouracil (5-FU) has long been used for the treatment of gastrointestinal tumors harboring interindividual variability in both the pharmacokinetic and the pharmacogenetic profiles, which in turn may lead to life-threatening toxicities. We carried out a… read more here.
Keywords: prospective cohort; treatment; toxicity; severe toxicity ... See more keywords
Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-22-0404
Abstract: Abstract Purpose: Adjuvant immunotherapy produces durable benefit for patients with resected melanoma, but many develop recurrence and/or immune-related adverse events (irAE). We investigated whether baseline serum autoantibody (autoAb) signatures predicted recurrence and severe toxicity in… read more here.
Keywords: recurrence; baseline serum; toxicity; severe toxicity ... See more keywords
Improving the tolerability of osimertinib by identifying its toxic limit
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359221103212
Abstract: Background: Osimertinib is the cornerstone in the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer (NSCLC). Nonetheless, ±25% of patients experience severe treatment-related toxicities. Currently, it is impossible to identify patients at risk… read more here.
Keywords: toxicity; severe toxicity; dose reduction; toxic limit ... See more keywords
Timing of Severe Toxicity from Chemotherapy in Patients With Lung Cancer
Sign Up to like & getrecommendations! Published in 2020 at "AntiCancer Research"
DOI: 10.21873/anticanres.14661
Abstract: Background/Aim: The aim of this study was to investigate the timing of severe toxicity in lung cancer patients receiving chemotherapy. Patients and Methods: Patients with advanced non-small cell lung cancer or limited disease small cell… read more here.
Keywords: chemotherapy; toxicity; severe toxicity; timing severe ... See more keywords